✦ LIBER ✦

LRRK2 is a component of granular alpha-synuclein pathology in the brainstem of Parkinson's disease

✍ Scribed by J. Alegre-Abarrategui; O. Ansorge; M. Esiri; R. Wade-Martins

Book ID: 110852545
Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 748 KB
Volume: 34
Category: Article
ISSN: 0305-1846
DOI: 10.1111/j.1365-2990.2007.00888.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Leucine-rich repeat kinase 2 (LRRK2): A

Leucine-rich repeat kinase 2 (LRRK2): A key player in the pathogenesis of Parkinson's disease

✍ Payal N. Gandhi; Shu G. Chen; Amy L. Wilson-Delfosse 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 209 KB

## Abstract Parkinson's disease (PD) is the most common neurodegenerative movement disorder, with a prevalence of more than 1% after the age of 65 years. Mutations in the gene encoding leucine‐rich repeat kinase‐2 (__LRRK2__) have recently been linked to autosomal dominant, late‐onset PD that is cl

Microtubule-associated protein 5 is a co

Microtubule-associated protein 5 is a component of Lewy bodies and Lewy neurites in the brainstem and forebrain regions affected in Parkinson's disease

✍ W. P. Gai; P. C. Blumbergs; W. W. Blessing 📂 Article 📅 1995 🏛 Springer-Verlag 🌐 English ⚖ 165 KB

Interaction of alpha-synuclein and dopam

Interaction of alpha-synuclein and dopamine metabolites in the pathogenesis of Parkinson’s disease: a case for the selective vulnerability of the substantia nigra

✍ James E. Galvin 📂 Article 📅 2006 🏛 Springer-Verlag 🌐 English ⚖ 509 KB

Functional changes of brainstem reflexes

Functional changes of brainstem reflexes in Parkinson's disease conditioning of the blink reflex R2 component by paired and index finger stimulation

✍ A. Lozza; J. L. Pepin; G. Rapisarda; A. Moglia; P. J. Delwaide 📂 Article 📅 1997 🏛 Springer 🌐 English ⚖ 597 KB

Lrrk2 R1441G-related Parkinson’s disease

✍ Ignacio F. Mata; Carolyn M. Hutter; María C. González-Fernández; Marian M. de Pa 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 169 KB

Fipamezole (JP-1730) is a potent α2 adre

Fipamezole (JP-1730) is a potent α2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease

✍ Juha-Matti Savola; Michael Hill; Mia Engstrom; Hannele Merivuori; Siegfried Wurs 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 148 KB

Previous studies in the MPTP-lesioned primate model of Parkinson's disease have demonstrated that alpha(2) adrenergic receptor antagonists such as idazoxan, rauwolscine, and yohimbine can alleviate L-dopa-induced dyskinesia and, in the case of idazoxan, enhance the duration of anti-parkinsonian acti